174 completed, 45 recruiting, 35 terminated, 13 active not recruiting. 300 Phase 1, 107 Phase 2.
Follow Blood Coagulation Disorders: new trials by email Literature Review of Blood Coagulation Disorders trials Research Report on Blood Coagulation Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lentiviral FIX Gene Therapy YUVA-GT-F901 - Hemophilia B | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2027-06-01 | 2026-08-26 |
| Lentiviral FVIII Gene Therapy YUVA-GT-F801 - Hemophilia A | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2027-06-01 | 2026-09-01 |
| Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias RXIM002 - Immune Thrombocytopenia (ITP) | Phase 1 | Not yet recruiting | RiboX Therapeutics Ltd. | 27 | 2027-02-01 | 2026-09-23 |
| A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA Velinotamig specified dose on specified days. - Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA) | Phase 1 / Phase 2 | Not yet recruiting | Cullinan Therapeutics Inc. | 72 | 2026-12-01 | 2026-07-31 |
| TGD001 Treatment in Thrombotic Microangiopathies TGD001 - Thrombotic Microangiopathies, ITP Immune-Mediated Thrombocytopenia | Phase 1 / Phase 2 | Not yet recruiting | TargED Biopharmaceuticals B.V. | 70 | 2026-10-31 | 2026-09-29 |
| "IL-1β Blockade to Prevent Immunothrombosis in Recipients of a Pancreatic Organ" Anakinra 100Mg/0.67Ml Inj Syringe - Pancreatic Transplant | Phase 1 / Phase 2 | Recruiting | Nantes University Hospital | 15 | 2026-10-07 | 2026-10-13 |
| Safely Quenching Complement in Stroke Survivors Pegcetacoplan Injection [Empaveli] - Acute Ischemic Stroke, Cerebral Infarction | Phase 1 | Not yet recruiting | Columbia University | 20 | 2026-10-01 | 2026-04-29 |
| A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A SPK-8011QQ - Hemophilia A | Phase 1 / Phase 2 | Recruiting | Hoffmann-La Roche | 5 | 2026-09-08 | 2026-10-13 |
| A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms DMR-001, Ruxolitinib - Myeloproliferative Neoplasms (MPNs) | Phase 1 | Recruiting | Damora Therapeutics | 250 | 2026-09-01 | 2026-10-27 |
| A First-in Human Study of ARD001 in Healthy Volunteers and People With Hemophilia A ARD001, Placebo - Hemophilia A, Healthy Adult Participants | Phase 1 / Phase 2 | Recruiting | Arditus Pte Ltd | 20 | 2026-08-01 | 2026-08-26 |
| Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease CTX112 - Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia | Phase 1 / Phase 2 | Recruiting | CRISPR Therapeutics AG | 60 | 2026-07-17 | 2026-10-20 |
| Bioequivalence Study of SKI-O-703 in Healthy Adults Under Fed Conditions SKI-O-703 API in Capsules, SKI-O-703 Formulated Granules in Capsules - Bioequivalence Study in Healthy Subjects, Immune Thrombocytopenia (ITP) | Phase 1 | Active not recruiting | Oscotec Inc. | 48 | 2026-07-10 | 2026-09-01 |
| A Clinical Study to Evaluate JCXH-213 in the Treatment of Adults With Primary Immune Thrombocytopenia JCXH-213 - Thrombocytopenic Purpura, Immune | Phase 1 | Not yet recruiting | The General Hospital of Western Theater Command | 4 | 2026-06-18 | 2026-06-03 |
| CD20 Monoclonal Antibody Combined With BTK Inhibitor for the Treatment of Refractory Immune-related Cytopenia Anti-CD20 monoclonal antibody and the BTK inhibitor - Anti-CD20 Monoclonal Antibody, BTK Inhibitors | Phase 1 | Not yet recruiting | Qi deng | 30 | 2026-06-01 | 2026-05-22 |
| Universal STAR-T Cell Injection in R/R Autoimmune Diseases. Universal STAR-T Cell - Immune Thrombocytopenia | Phase 1 | Not yet recruiting | Jian Zhu | 6 | 2026-05-11 | 2026-05-20 |
| Study of INCA036978 in Participants With Myeloproliferative Neoplasms INCA036978, Standard disease-directed therapy - Myeloproliferative Neoplasms | Phase 1 | Recruiting | Incyte Corporation | 218 | 2026-05-11 | 2026-10-09 |
| Safety and Tolerability of ZE74-0282 in Healthy Volunteers ZE74-0282-0001 or placebo - Healthy Volunteers | Phase 1 | Recruiting | Eilean Therapeutics AU Pty Ltd | 64 | 2026-04-16 | 2026-07-28 |
| Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia GL-2045 - Immune Thrombocytopenia | Phase 1 | Recruiting | Gliknik Inc. | 42 | 2026-04-14 | 2026-05-26 |
| Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia Zanubrutinib 80mg/d, High dose dexamethasone, Zanubrutinib 160mg/d - Immune Thrombocytopenia | Phase 1 | Not yet recruiting | Peking University People's Hospital | 60 | 2025-12-25 | 2026-01-02 |
| A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia CM336 Injection - Autoimmune Cytopenia, Immune Thrombocytopenia (ITP) | Phase 1 / Phase 2 | Recruiting | Keymed Biosciences Co.Ltd | 158 | 2025-11-18 | 2025-12-17 |
Showing 20 of 300. Sign in to see all of them.
Hemophilia A (98) · Thrombocythemia, Essential (68) · Purpura, Thrombocytopenic, Idiopathic (63) · Primary Myelofibrosis (61) · Myeloproliferative Disorders (55) · Polycythemia Vera (55) · Hemophilia B (52) · Leukemia, Myeloid, Acute (39) · Leukemia, Myelomonocytic, Chronic (34) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (33) · Myelodysplastic Syndromes (32) · Leukemia, Lymphocytic, Chronic, B-Cell (29) · Leukemia (28) · Multiple Myeloma (27) · Burkitt Lymphoma (26)
Hemic and Lymphatic Diseases (300) · Hematologic Diseases (284) · Hemorrhagic Disorders (277) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (174) · Genetic Diseases, Inborn (150) · Blood Coagulation Disorders, Inherited (146) · Blood Platelet Disorders (141) · Coagulation Protein Disorders (129) · Pathological Conditions, Signs and Symptoms (128) · Pathologic Processes (126) · Immune System Diseases (111) · Cytopenia (77) · Signs and Symptoms (69) · Hemorrhage (68)
Factor VIII (16) · Peripheral Blood Stem Cell Transplantation (9) · ruxolitinib (9) · eltrombopag (8) · Cyclosporine (7) · F8 protein, human (7) · Cyclophosphamide (6) · Injections (6) · Busulfan (5) · fludarabine phosphate (5) · recombinant factor VIII N8 (5) · Antilymphocyte Serum (4) · BIVV001 (4) · Decitabine (4) · Filgrastim (4)
Novo Nordisk A/S (27) · Bayer (13) · Baxalta now part of Shire (8) · National Cancer Institute (NCI) (7) · Pfizer (7) · GlaxoSmithKline (6) · Eli Lilly and Company (5) · Incyte Corporation (5) · Peking University People's Hospital (5) · Eisai Inc. (4) · Fred Hutchinson Cancer Center (4) · Hangzhou Gensciences Biopharmaceutical Co., Ltd. (4) · BioMarin Pharmaceutical (3) · Bioverativ Therapeutics Inc. (3) · Bioverativ, a Sanofi company (3)
United States (153) · United Kingdom (58) · China (47) · Germany (43) · Spain (34) · Italy (30) · France (28) · Australia (23) · Bulgaria (22) · Canada (19) · Japan (16) · Netherlands (14) · Austria (13) · Belgium (13) · Poland (12)
Lei Zhang, MD (3) · Franklin Johnson (2) · Gilbert C. White (2) · Iris Jacobs, MD (2) · Jacob H Grauslund, MD (2)
PMID 25495795, PMID 35075289, PMID 17880439, PMID 22149959, PMID 29224506, PMID 35857660, PMID 36796484, PMID 39642315, PMID 40386832, PMID 42698050, PMID 12752100, PMID 1374895, PMID 15230949, PMID 1538192, PMID 15570084, PMID 15577929, PMID 15870545, PMID 16375711, PMID 17090654, PMID 17961193, PMID 19127265, PMID 19138379, PMID 19208097, PMID 19372317, PMID 19846889, PMID 20133895, PMID 21443634, PMID 22110246, PMID 22223821, PMID 22259028, PMID 22353395, PMID 22859609, PMID 23398640, PMID 23777763, PMID 23829485, PMID 23855900, PMID 23863832, PMID 24474568, PMID 24559067, PMID 24802773, PMID 24843882, PMID 24846496, PMID 25409372, PMID 25426834, PMID 25563429, PMID 25641556, PMID 25762180, PMID 26093876, PMID 26157075, PMID 26210442
2015 (7), 2018 (7), 2014 (6), 2023 (6), 2009 (5), 2016 (3), 2017 (3), 2005 (2), 2008 (2), 2019 (2), 2025 (2), P30CA015083 (2), U01CA062491 (2), P01CA018029 (1), P01CA108671 (1)